首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

2107762

次發性副甲狀腺機能亢進治療市場：依藥物類別、通路及地區分類

Secondary Hyperparathyroidism Treatment Market, By Drug Class, By Distribution Channel, By Geography

出版日期: 2026年07月24日 | 出版商:

Coherent Market Insights | 英文 257 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，次發性副甲狀腺機能亢進治療市場規模將達到 51.3 億美元，到 2033 年將達到 81.4 億美元。預計 2026 年至 2033 年的複合年成長率將達到 6.8%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	51.3億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	6.80%	2033年市場規模預測：	81.4億美元

市場成長主要受以下因素驅動：慢性腎臟病盛行率不斷上升、透析依賴患者數量不斷增加、與慢性腎臟病相關的礦物質和骨骼代謝紊亂診斷數量不斷增加，以及維生素 D粘合劑、擬鈣劑和磷酸鹽結合劑的廣泛應用。

次發性副甲狀腺機能亢進的特徵是由於鈣、磷、維生素D和礦物質代謝異常導致副甲狀腺素分泌過多。這種疾病在晚期慢性腎臟病病患者或接受透析治療的患者中更為常見。治療主要集中在控制副甲狀腺素水平、維持鈣磷平衡、預防骨骼併發症以及降低與礦物質失衡相關的心血管風險。

此市場涵蓋多種治療方案，例如維生素D衍生物（包括骨化三醇、多塞骨化醇和帕立骨化醇）、鈣敏感受體激動劑、鈣基磷酸鹽粘合劑和非鈣基磷酸鹽粘合劑。治療方案的選擇通常取決於患者的副甲狀腺素水平、血清鈣磷水平、維生素D狀態、腎臟疾病分期、是否接受透析治療、治療耐受性以及骨骼和心血管併發症的整體風險。

醫療專業人員正日益採用個人化治療策略，包括定期生化監測、劑量調整、聯合治療以及透析期間的藥物綜合給藥。差異化鈣敏感受體激動劑、磷酸鹽吸收抑制劑、緩釋維生素D製劑以及透析期間給藥療法的研發，正在拓展可用的治療選擇範圍。

次發性副甲狀腺機能亢進透析治療和醫療機構的保險報銷體系，這也影響了藥物購買和治療的可及性。由於需要專家監督、注射藥物的給藥、實驗室檢測監測以及定期調整治療方案，醫院藥局和透析中心仍然是重要的藥物分發中心。

市場動態

由於慢性腎臟病病率上升以及需要透析的患者數量增加，次發性副甲狀腺機能亢進治療市場呈現穩定成長動能。腎功能進行性下降會導致磷儲存、維生素D活化降低、鈣失衡、副甲狀腺素分泌過多。這些併發症使得對維生素D衍生物、擬鈣劑、磷酸鹽粘合劑、臨床實驗室監測以及在重症和難治性病例中進行外科手術的需求持續存在。

慢性腎臟病相關礦物質和骨骼代謝紊亂的診斷數量不斷增加，促使人們更需要對次發性副甲狀腺機能亢進進行早期和持續的管理。腎臟科醫師和透析照護團隊越來越重視監測副甲狀腺素、鈣、磷、維生素D、骨骼代謝和心血管風險。這種方法提倡個人化治療方案的選擇和聯合治療的應用，而不是依賴單一類型的藥物。

透析基礎設施的擴張也推動了市場成長。醫院、門診透析中心、腎臟護理診所和院內藥房在注射給藥、配製口服藥物、監測生化指標和調整治療方案方面發揮著至關重要的作用。隨著已開發市場和新興市場透析設施數量的增加，次發性副甲狀腺機能亢進的治療應用預計將會擴大。

鈣敏感受體激動劑療法的進展正在拓展血液透析患者的治療選擇。新型靜脈注射和差異化鈣敏感受體激動劑的研發旨在實現更穩定的副甲狀腺素控制、提高患者用藥依從性，並可在透析過程中給藥。這些療法有望減少患者對口服藥物的依賴，並促進透析中心治療的標準化。

聯合治療的日益普及是另一個重要的市場趨勢。維生素D衍生物、擬鈣劑和磷控制療法的聯合應用越來越普遍，這種療法既能控制副甲狀腺素水平，又能維持可接受的鈣磷水平。這推動了個人化治療方案的製定，並創造了對多種藥物類別的需求。

此外，作用機制不同於傳統磷粘合劑的新型磷控制療法的研發也對市場產生了正面影響。這些產品為對傳統粘合劑反應不佳、或有耐受性問題或用藥負擔的患者提供了更多治療選擇。

然而，市場成長受到許多因素的阻礙，例如治療費用高昂、早期慢性腎臟病診斷困難、某些藥物的副作用、複雜的劑量調整需求、磷酸鹽粘合劑帶來的用藥負擔，以及發展中國家透析和腎臟護理服務取得受限等。

由於北美擁有完善的透析基礎設施、龐大的腎衰竭患者群體、廣泛的繼發次發性副甲狀腺機能亢進治療、常規的生化監測以及完善的保險報銷體系，預計北美仍將是重要的區域市場。亞太地區預計將實現最快的成長，這得益於透析服務的普及、政府對腎臟護理投入的增加、診斷技術的進步以及先進療法的推廣。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據公司概況、產品系列、主要亮點、財務績效和策略等參數，對次發性副甲狀腺機能亢進治療市場的主要參與者進行了分析。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
《次發性副甲狀腺機能亢進治療市場》報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員將能夠透過分析次發性副甲狀腺機能亢進治療市場中使用的各種策略矩陣，做出更順利的決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

熱圖分析
市佔率分析
公司簡介
- AbbVie, Inc.
- Shire, Inc.
- OPKO Health
- Amgen, Inc.
- Sanofi SA
- F. Hoffmann-La Roche AG
- Kyowa Hakko Kirin Co. Ltd.
- KAI Pharmaceuticals
- Astellas Pharma, Inc.
- Deltanoid Pharmaceuticals
- Leo Pharma
分析師意見

第8章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI1570

Secondary Hyperparathyroidism Treatment Market is estimated to be valued at USD 5.13 Bn in 2026 and is expected to reach USD 8.14 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.8% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 5.13 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	6.80%	2033 Value Projection:	USD 8.14 Bn

Market growth is mainly driven by the increasing prevalence of chronic kidney disease, expansion of the dialysis-dependent patient population, growing diagnosis of chronic kidney disease-mineral and bone disorder, and rising adoption of vitamin D derivatives, calcimimetics, and phosphate binders.

Secondary hyperparathyroidism is characterized by excessive secretion of parathyroid hormone due to disturbances in calcium, phosphate, vitamin D, and mineral metabolism. The condition is commonly observed among patients with advanced chronic kidney disease and those undergoing dialysis. Treatment primarily focuses on controlling parathyroid hormone levels, maintaining calcium and phosphate balance, preventing bone complications, and reducing cardiovascular and vascular risks associated with mineral imbalance.

The market includes a wide range of treatment options, including vitamin D derivatives such as calcitriol, doxercalciferol, and paricalcitol; calcimimetics; calcium-based phosphate binders; and non-calcium-based phosphate binders. Treatment selection generally depends on the patient's parathyroid hormone level, serum calcium and phosphate levels, vitamin D status, kidney disease stage, dialysis status, treatment tolerance, and overall risk of bone and cardiovascular complications.

Healthcare providers are increasingly adopting individualized treatment strategies involving regular biochemical monitoring, dosage adjustment, combination therapy, and dialysis-integrated drug administration. The development of differentiated calcimimetics, phosphate absorption inhibitors, extended-release vitamin D formulations, and dialysis-administered therapies is expanding the available treatment landscape.

The growing integration of secondary hyperparathyroidism medicines into institutional dialysis care and reimbursement frameworks is also influencing product procurement and treatment utilization. Hospital pharmacies and dialysis facilities remain important distribution points due to the requirement for specialist supervision, injectable drug administration, laboratory monitoring, and regular treatment modification.

Market Dynamics

The secondary hyperparathyroidism treatment market is witnessing steady momentum owing to the rising prevalence of chronic kidney disease and the expanding population of patients requiring dialysis. Progressive loss of kidney function results in phosphate retention, reduced vitamin D activation, calcium imbalance, and excessive secretion of parathyroid hormone. These complications create sustained demand for vitamin D derivatives, calcimimetics, phosphate binders, laboratory monitoring, and surgical intervention in severe or treatment-resistant cases.

The increasing diagnosis of chronic kidney disease-related mineral and bone disorders is strengthening the demand for early and continuous management of secondary hyperparathyroidism. Nephrologists and dialysis care teams are placing greater emphasis on monitoring parathyroid hormone, calcium, phosphate, vitamin D, bone metabolism, and cardiovascular risk. This approach is encouraging personalized treatment selection and the use of combination therapies rather than dependence on a single drug class.

The expansion of dialysis infrastructure is also supporting market growth. Hospitals, outpatient dialysis centres, renal-care clinics, and institutional pharmacies play an important role in administering injectable therapies, dispensing oral medicines, monitoring biochemical parameters, and adjusting treatment regimens. Growth in the number of dialysis facilities across developed and emerging markets is expected to increase the utilization of secondary hyperparathyroidism treatments.

Advancements in calcimimetic therapies are expanding the treatment options available for patients receiving hemodialysis. Newer intravenous and differentiated calcimimetics are being developed to provide more consistent parathyroid hormone control, improve adherence, and enable treatment administration during dialysis sessions. These therapies may reduce dependence on patient-managed oral dosing and support greater treatment standardization within dialysis facilities.

The rising use of combination treatment approaches is another important market trend. Vitamin D derivatives, calcimimetics, and phosphate-management therapies are increasingly used together to control parathyroid hormone levels while maintaining acceptable calcium and phosphate concentrations. This supports individualized treatment planning and creates demand across multiple drug classes.

The market is also benefiting from the development of phosphate-management therapies with mechanisms that differ from traditional phosphate binders. Such products are expanding treatment choices for patients who do not respond adequately to conventional binders or experience tolerability and pill-burden challenges.

However, market growth is affected by the high cost of treatment, limited diagnosis during the early stages of chronic kidney disease, adverse effects associated with certain medicines, complex dose-adjustment requirements, high phosphate-binder pill burden, and restricted access to dialysis and renal-care services in developing markets.

North America is expected to remain the leading regional market due to its established dialysis infrastructure, large kidney-failure population, broad availability of secondary hyperparathyroidism medicines, regular biochemical monitoring, and structured reimbursement environment. Asia Pacific is expected to record the fastest growth, supported by expanding dialysis access, increasing government investment in renal care, improving diagnosis, and wider availability of advanced treatments.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Secondary Hyperparathyroidism Treatment Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AbbVie, Inc., Shire, Inc., OPKO Health, Amgen, Inc., Sanofi SA, F. Hoffmann-La Roche AG, Kyowa Hakko Kirin Co. Ltd., KAI Pharmaceuticals, Astellas Pharma, Inc., Deltanoid Pharmaceuticals, and Leo Pharma
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Secondary Hyperparathyroidism Treatment Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Secondary Hyperparathyroidism Treatment Market

Market Segmentation

By Drug Class (Revenue, USD Bn, 2021-2033)
Vitamin D Derivatives
- Calcitriol
- Doxercalciferol
- Paracalcitol
Calcimimetics
Phosphate Binders
- Calcium-Based Binders
- Non-Calcium Based Binders
By Distribution Channel (Revenue, USD Bn, 2021-2033)
Hospital Pharmacies
Retail Pharmacies
E-Commerce
By Region (Revenue, USD Bn, 2021-2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Key Players
AbbVie, Inc.
Shire, Inc.
OPKO Health
Amgen, Inc.
Sanofi SA
Hoffmann-La Roche AG
Kyowa Hakko Kirin Co. Ltd.
KAI Pharmaceuticals
Astellas Pharma, Inc.
Deltanoid Pharmaceuticals,
Leo Pharma

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Secondary Hyperparathyroidism Treatment Market, By Drug Class, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Vitamin D Derivatives
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  - Calcitriol
  - Doxercalciferol
  - Paracalcitol
Calcimimetics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Phosphate Binders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  - Calcium-Based Binders
  - Non-Calcium Based Binders

5. Global Secondary Hyperparathyroidism Treatment Market, By Distribution Channel, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
E-Commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Secondary Hyperparathyroidism Treatment Market, By Region, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- AbbVie, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Shire, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- OPKO Health
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Amgen, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Sanofi SA
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- F. Hoffmann-La Roche AG
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Kyowa Hakko Kirin Co. Ltd.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- KAI Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Astellas Pharma, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Deltanoid Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Leo Pharma
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
Analyst Views